<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050033</url>
  </required_header>
  <id_info>
    <org_study_id>DO608679A</org_study_id>
    <nct_id>NCT04050033</nct_id>
  </id_info>
  <brief_title>Evoke Radiofrequency Device for Improvement of Skin Appearance</brief_title>
  <official_title>Clinical Study to Evaluate the Performance of Evoke Radiofrequency Device for Improvement of Skin Appearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the safety, efficacy, patient comfort and patient&#xD;
      satisfaction after Evoke treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Change in Skin Appearance</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>Picture evaluation by blinded investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate rate of Change in Skin Appearance using 3D Photographic analysis</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>3D Photographic analysis will be conducted using QuantifiCare System</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate changes in skin using VivoSight Optical Coherence Tomography (OCT) software</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>Non-invasive in vivo skin imaging will be taken with the VivoSight Optical Coherence Tomography (OCT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate changes in skin appearance comparing photographs using Mechanical Turk (MTurk). The pictures will be sent through the system and evaluated by crowd workers.</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>The pictures will be sent through the system and evaluated by crowd workers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Investigator assessment of the skin appearance improvement</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Investigator assessment of the skin appearance improvement comparing pre and post treatment using 0 - 4 -points Likert scale at 1 month, 3 months and 6 months follow up visits:&#xD;
• 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Subject assessment of improvement and satisfaction</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Improvement assessment will be performed independently by the subject himself 4 points Likert scale questionnaire (Global Aesthetic Improvement Scale), as follows:&#xD;
• 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference.&#xD;
Subject assessment of satisfaction will be filled out by subjects using a 5-points Likert scale, as follows:&#xD;
• +2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate histological changes to treatment area skin</measure>
    <time_frame>3 Months</time_frame>
    <description>Positive changes in histologic evaluation: up to 5 subjects will undergo biopsies of the treated area for histology at baseline and at 3M follow-up visit. Histological sections will be stained using elastin, H&amp;E and other collagen specific stains.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Improvement of Skin Appearance</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments (Tx.1, Tx.2 and Tx.3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evoke Device</intervention_name>
    <description>Subjects will undergo treatment with Evoke Device</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Signed informed consent to participate in the study.&#xD;
&#xD;
          -  Female and male subjects, 35 - 75 years of age at the time of enrolment&#xD;
&#xD;
          -  If female, not pregnant, lactating and must be either post-menopausal, surgically&#xD;
             sterilized, or using a medically acceptable form of birth control at least 3 months&#xD;
             prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods&#xD;
             with spermicide or abstinence).&#xD;
&#xD;
          -  In addition, negative urine pregnancy test as tested before each treatment and at the&#xD;
             last visit for women with childbearing potential (e.g. not menopause).&#xD;
&#xD;
          -  General good health confirmed by medical history and skin examination of the treated&#xD;
             area.&#xD;
&#xD;
          -  Willing to have photographs and images taken of the treated areas to be used&#xD;
             de-identified in evaluations, publications and presentations.&#xD;
&#xD;
          -  The patients should be willing to comply with the study procedure and schedule,&#xD;
             including the follow up visit, and will refrain from using any other aesthetic&#xD;
             treatment methods for the last 6 months and during the entire study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pacemaker or internal defibrillator, or any other active electrical implant anywhere&#xD;
             in the body.&#xD;
&#xD;
          -  Permanent implant in the treated area such as metal plates and screws, silicone&#xD;
             implants or an injected chemical substance, unless deep enough in the periostal plane.&#xD;
&#xD;
          -  Current or history of skin cancer, or current condition of any other type of cancer,&#xD;
             or premalignant moles.&#xD;
&#xD;
          -  Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled&#xD;
             hypertension, and liver or kidney diseases.&#xD;
&#xD;
          -  Pregnancy and nursing.&#xD;
&#xD;
          -  Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use&#xD;
             of immunosuppressive medications.&#xD;
&#xD;
          -  Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex&#xD;
             in the treatment area, may be treated only following a prophylactic regimen.&#xD;
&#xD;
          -  Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.&#xD;
&#xD;
          -  Any active condition in the treatment area, such as sores, psoriasis, eczema, and&#xD;
             rash.&#xD;
&#xD;
          -  History of skin disorders, keloids, abnormal wound healing, as well as very dry and&#xD;
             fragile skin.&#xD;
&#xD;
          -  History of bleeding coagulopathies or use of anticoagulants in the last 10 days.&#xD;
&#xD;
          -  Any surgery in treated area within 3 months prior to treatment.&#xD;
&#xD;
          -  Six months delay is required if other recent treatments like light, CO2 laser or RF&#xD;
             were performed on the same area.&#xD;
&#xD;
          -  Use of Isotretinoin (Accutane®) within 6 months prior to treatment.&#xD;
&#xD;
          -  As per the practitioner's discretion, refrain from treating any condition that might&#xD;
             make it unsafe for the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erez Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Avance Plastic Surgery Institute 5570 Longley Lane, Suite A Reno, NV 89511</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Chia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BodySculpt 128 Central Park S New York, NY 10019</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avance Plastic Surgery Institute</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Square Laser Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BodySculpt</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

